DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Post comments:0 Comments Continue ReadingDNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.